title: Administration of FGF-1 through transfected cells alleviates MPTP toxicity in mice.
abstract: The use of genetically modified cells to deliver growth factors has been proposed as a possible treatment for neurodegeneration, including Parkinson's disease. Here we demonstrate that the implantation of fibroblasts genetically modified to secrete fibroblast growth factor-1 (FGF) increased striatal dopamine concentrations in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mouse model of Parkinson's disease.
authors.affiliation: Tulane University School of Medicine and New Orleans V.A. Medical Center, New Orleans, LA 70152, USA. james.zadina@tulane.edu
authors.forename: R N
authors.initials: RN
authors.lastname: McLay
authors.forename: S M
authors.initials: SM
authors.lastname: Freeman
authors.forename: J E
authors.initials: JE
authors.lastname: Zadina